摘要
目的研究头孢哌酮/舒巴坦在慢性心力衰竭并发肺部感染中的疗效,掌握科学的治疗方法。方法随机选取医院2010年1月-2012年12月收治的由慢性心力衰竭并发的肺部感染患者60例,将其随机分为对照组和试验组,每组各30例,分别给予头孢哌酮和头孢哌酮/舒巴坦治疗,然后对两组进行疗效比较。结果试验组的痊愈率为80.0%,有效率为93.3%;对照组的痊愈率为56.7%,有效率为76.7%,差异有统计学意义(P<0.05);试验组各项观察指标的症状减轻或消失的时间均少于对照组所用时间,对治疗有积极意义,差异有统计学意义(P<0.05)。结论头孢哌酮/舒巴坦在对慢性心力衰竭并发肺部感染的临床疗效要优于头孢哌酮。
OBJECTIVE To study the efficacy of cefoperazone/sulbactam in treatment of chronic heart failure complicated with pulmonary infections and master the scientific treatment. METHODS A total of 60 cases of patients with chronic heart failure complicated by lung infections were randomly selected from the patients who were enroll the hospital from Jan 2010 to Dec 2012, and randomly divided into the control group and the experimental groups, with 30 cases in each group. They were respectively treated with cefoperazone and cefoperazone/sulbactam. The efficacy of the two groups was compared. RESULTS The cure rate of the experimental group was 80.0%, the effective rate was 93.3% % the cure rate of the control group was 56.7%, the effective rate was 76.7%, with statistical significance （P〈0.05）. The time for disappearance or alleviation of symptoms of the monitoring indicators was shorter in the experimental group than in the control group,which was great significance in the treatment, the difference was statistically significant （P%0.05）. CONCLUSION The efficacy of cefoperazone/sulbactam is superior to cefoperazone in the treatment of COPD complicated with pulmonary infections, it is worthy of the clinical promotion.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2013年第1期172-174,共3页
Chinese Journal of Nosocomiology
